IP Library Granted Patent US 12,239,807
Granted Patent B2
US 12,239,807 · App. 16/989,208 · Granted Mar 4, 2025

Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems

Inventors: Heejin Lee (Bedford, MA); Karen Daniel (Newton, MA)
Assignee: TARIS Biomedical LLC
A61M31/002A61K9/0034A61M25/0009A61M2205/0216A61M2207/00A61M2210/1085
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,807
App. No.
16/989,208
Granted
Mar 4, 2025
Kind
B2
Abstract

Intravesical drug delivery devices are provided which may include an elongated body formed of a matrix system of a drug dispersed in a silicone, wherein the elongated body has a first end, an opposed second end, and an intermediate portion between the first and second ends, and wherein the silicone of the matrix system is cured to bias the elongated body in a coiled retention shape, such that the device is elastically deformable between a relatively straightened shape suited for insertion of the device through a urethra and into the urinary bladder of a patient and the coiled retention shape which is suited to retain the device within the urinary bladder.

Claims (30)

1. An intravesical drug delivery device comprising:

an elongated body formed of a matrix system of a drug dispersed in a silicone, the elongated body having a first end, an opposed second end, and an intermediate portion between the first and second ends; and

an elastic retention frame associated with the elongated body and effective to bias the elongated body into a coiled retention shape,

wherein the elastic retention frame is disposed within a lumen sealed at its ends and defined by an annular tube which is located within the matrix system, the lumen extending in a direction from the first end to the second end.

2. The device of claim 1 , wherein the elastic retention frame comprises a nitinol wire or other superelastic wire.

3. The device of claim 1 , further comprising an outer wall layer that covers at least the intermediate portion, wherein the outer wall layer comprises a water- and drug-permeable polymeric material.

4. The device of claim 1 , wherein the silicone is a high durometer silicone.

5. The device of claim 1 , wherein the drug comprises from 1 wt % to 20 wt % of the matrix system.

6. A method of administering a drug to a patient in need thereof, comprising:

inserting into the patient the intravesical device of claim 1 , by passing the device through the patient's urethra and into the patient's urinary bladder; and

releasing the drug from the device to a tissue site within the patient.

7. An intravesical drug delivery device comprising:

an elongated body formed of a matrix system of a drug dispersed in a silicone, the elongated body having a first end, an opposed second end, and an intermediate portion between the first and second ends;

an elastic retention frame associated with the elongated body and effective to bias the elongated body into a coiled retention shape; and

an outer wall layer that covers at least the intermediate portion, wherein the outer wall layer comprises a water- and drug-permeable polymeric material,

wherein the elastic retention frame comprises a nitinol wire or other superelastic wire,

wherein the nitinol wire or other superelastic wire is disposed within a lumen which is adjacent to the elongated body, the lumen extending in a direction from the first end to the second end and being defined by an annular tube which is formed of the water- and drug-permeable polymeric material.

8. An intravesical drug delivery device comprising:

an elongated body formed of a matrix system of a drug dispersed in a biocompatible polymer, the elongated body having a first end, an opposed second end, and an intermediate portion between the first and second ends; and

an elastic retention frame associated with the elongated body and effective to bias the elongated body into a coiled retention shape,

wherein the matrix system extends from the first end to the second end, and

wherein the elastic retention frame is disposed within a lumen sealed at its ends and defined by an annular tube which is located within the matrix system, the lumen extending in a direction from the first end to the second end.

9. The device of claim 8 , wherein the biocompatible polymer comprises a polyurethane.

10. An intravesical drug delivery device comprising:

an elongated body formed of a matrix system of a drug dispersed in a non-bioerodible, biocompatible polymer, the elongated body having a first end and an opposed second end wherein the matrix system extends continuously between the first end and the second end,

wherein the polymer of the matrix system biases the device in a retention shape, such that the device is elastically deformable between a relatively straightened shape suited for insertion of the device through the urethra and into the urinary bladder of a patient and the retention shape which is suited to retain the device within the urinary bladder.

11. The intravesical drug delivery device of claim 10 , wherein the biocompatible polymer comprises a silicone or a polyurethane.

12. The intravesical drug delivery device of claim 10 , wherein the drug is present in the matrix system in an amount from 1% to 20% by weight.

13. The intravesical drug delivery device of claim 10 , wherein the retention shape is coiled and the elongated body is from 10 cm to 15 cm in length.

14. The intravesical drug delivery device of claim 10 , wherein the polymer of the matrix system has a durometer value from 45 Shore A to 88 Shore A.

Assignments (3)
MERGER Recorded May 14, 2026
From: TARIS BIOMEDICAL LLC
To: JANSSEN BIOTECH, INC.
Reel/Frame 074655/0466 →
MERGER Recorded May 12, 2026
From: TARIS BIOMEDICAL LLC
To: JANSSEN BIOTECH, INC.
Reel/Frame 074630/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2020
From: LEE, HEEJIN; DANIEL, KAREN
To: TARIS BIOMEDICAL LLC
Reel/Frame 053458/0344 →
Continuity (3)
Division 15321110
Provisional Application 62017775 · Jun 26, 2014
Related Publication 20200368508A1 · Nov 26, 2020
References Cited (47)
US 3854480A · Zaffaroni · 1974 [cited by examiner]
US 4871542A · Vilhardt · 1989 [cited by applicant]
US 5062829A · Pryor · 1991 [cited by examiner]
US 5694947A · Lehtinen · 1997 [cited by applicant]
US 6039967A · Ottoboni et al. · 2000 [cited by applicant]
US 6183461B1 · Matsuura et al. · 2001 [cited by applicant]
US 6524608B2 · Ottoboni et al. · 2003 [cited by applicant]
US 7077859B2 · Sirhan et al. · 2006 [cited by applicant]
US 7288084B2 · Li · 2007 [cited by applicant]
US 8343516B2 · Daniel et al. · 2013 [cited by applicant]
US 8679094B2 · Cima et al. · 2014 [cited by applicant]
US 8690840B2 · Lee et al. · 2014 [cited by applicant]
US 8801694B2 · Lee et al. · 2014 [cited by applicant]
US 9017312B2 · Lee et al. · 2015 [cited by applicant]
US 9107816B2 · Lee et al. · 2015 [cited by applicant]
US 9283361B2 · DiCesare et al. · 2016 [cited by applicant]
US 9586035B2 · Cima et al. · 2017 [cited by applicant]
US 20040022824A1 · Li · 2004 [cited by examiner]
US 20040122507A1 · Henderson · 2004 [cited by applicant]
US 20060025726A1 · Fischer, Jr. · 2006 [cited by examiner]
US 20060052757A1 · Fischer et al. · 2006 [cited by applicant]
US 20060105010A1 · Rahe et al. · 2006 [cited by applicant]
US 20060122689A1 · Kocur et al. · 2006 [cited by applicant]
US 20070161968A1 · Fischer, Jr. · 2007 [cited by applicant]
US 20090149833A1 · Cima · 2009 [cited by examiner]
US 20100331770A1 · Lee et al. · 2010 [cited by applicant]
US 20110060309A1 · Lee · 2011 [cited by applicant]
US 20120089121A1 · Lee · 2012 [cited by applicant]
US 20120089122A1 · Lee · 2012 [cited by examiner]
US 20120107385A1 · Mahashabde et al. · 2012 [cited by applicant]
US 20120203203A1 · Lee · 2012 [cited by examiner]
US 20130158675A1 · Hutchins, III et al. · 2013 [cited by applicant]
US 20130324946A1 · Tobias et al. · 2013 [cited by applicant]
US 20140209100A1 · Kiser et al. · 2014 [cited by applicant]
US 20140242044A1 · Evans · 2014 [cited by examiner]
US 20140276636A1 · Lee et al. · 2014 [cited by applicant]
US 20150080847A1 · Cima et al. · 2015 [cited by applicant]
US 20150209277A1 · Lee et al. · 2015 [cited by applicant]
US 20160008271A1 · Lee · 2016 [cited by applicant]
US 20160199544A1 · Lee et al. · 2016 [cited by applicant]
US 20160310715A1 · Lee · 2016 [cited by applicant]
WO 2012048104A1 · 2012 [cited by applicant]
WO 2013177068A1 · 2013 [cited by applicant]
WO 2015175538A1 · 2015 [cited by applicant]
International Search Report and Written Opinion in Corresponding PCT application PCT/US2015/037887, mailed Nov. 26, 2015. [cited by applicant]
Lee et al, “An intravesical device for the sustained delivery of lidocaine to the bladder”, Journal of Controlled Release, 2011, vol. 149, No. 2, pp. 133-139. [cited by applicant]
Tyagi et al, “Urodynamic and Immunohistochemical Evaluation of Intravesical Capsaicin Delivery Using Thermosensitive Hydrogel and Liposomes”, Journal of Urology, 2004, vol. 171, No. 1, pp. 483-489. [cited by applicant]